Injectable Formulation Articles & Analysis
9 news found
As the new academic year looms on the horizon, CD Formulation is ecstatic to announce a special Back to School Promotion 2024. ...
With a focus on sustained and controlled release formulations, as well as liquid, semi-solid, injectable, and nanoformulations, CD Formulation is at the forefront of the industry's efforts to enhance drug efficacy. ...
This innovation is particularly promising for delivering sensitive drugs that may degrade when exposed to traditional injection methods. For drugs that require a solid delivery system, CD Formulation has developed solid microneedle technology. ...
Long-Acting Controlled-Release Injection Technologies Another groundbreaking development by CD Formulation is its long-acting controlled-release injection technologies. By combining the benefits of sustained release with the ease of injection, CD Formulation has developed a solution that addresses the limitations ...
These include favoring agents, dispersion excipients, solubilizer excipients, surfactants, suspending agents, effervescents, emulsifiers, wetting agents, and preservatives. Excipients for Injections & Sterile Formulation For injections and sterile formulations, CD Formulation provides excipients that maintain ...
This formulation (Bupigel) prolonged bupivacaine release from the formulation in dissolution-like studies in vitro and analgesia in vivo in mouse, rat, and pig models. ...
Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. ...
OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. ...
CJ Wang, CEO, Frontier Biotechnologies said, "Today's announcement marks an important milestone in our efforts to create a long-acting injectable for treatment-experienced PLHIV (Patients Living with HIV) and critically ill, hospitalized AIDS patients who have limited choices for antiretroviral treatment. ...